4 recruiting. 4 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 4 |
| Phase 2 | 2 | Recruiting 2 |
Follow MK-8748: new trials by email Literature Review of MK-8748 trials Research Report on MK-8748
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005) MK-8748, Aflibercept - Diabetic Retinopathy, Macular Edema | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1104 | 2026-09-25 | 2026-11-03 |
| A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004) MK-8748, Aflibercept - Diabetic Retinopathy, Macular Edema | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 960 | 2026-08-27 | 2026-11-03 |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) Tiespectus, Aflibercept - Macular Degeneration, Age-Related Macular Degeneration | Phase 2 / Phase 3 | Recruiting | EyeBiotech Ltd. | 960 | 2026-04-15 | 2026-08-06 |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) Tiespectus, Aflibercept - Macular Degeneration, Age-Related Macular Degeneration | Phase 2 / Phase 3 | Recruiting | EyeBiotech Ltd. | 960 | 2026-03-27 | 2026-10-02 |
Choroidal Neovascularization (2) · Diabetic Retinopathy (2) · Macular Degeneration (2) · Macular Edema (2) · Wet Macular Degeneration (2)
EyeBiotech Ltd. (2) · Merck Sharp & Dohme LLC (2)
United States (4) · Argentina (2) · Australia (2) · Spain (2) · United Kingdom (2) · Brazil (1) · Colombia (1) · Czechia (1) · Estonia (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Latvia (1)